Alerta

IMPROVED ANTIBODY SPECIFICALLY BINDING TO AMYLOID-BETA OLIGOMERS

Resumen de: US20260285954A1

The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.

COMPOSITIONS AND METHODS FOR DIAGNOSING, TREATING, AND PREVENTING LYSOSOMAL STORAGE DISEASES

Resumen de: US20260286363A1

0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.

POTENCY ASSAY MATRIX FOR NEURONAL CELLS

Resumen de: US20260287576A1

0000 The invention provides, in some embodiments, a potency assay matrix for assessing potency of dopaminergic neuronal progenitor cells (DANPCs) that are intended for use in treating a neurodegenerative disease such as Parkinson's Disease. The potency assay matrix can include a bioassay for L-DOPA decarboxylase (DDC) activity. In addition to the DDC activity assay matrix, the potency assay matrix may also include one or more additional mechanism of action-based assays such as bioinformatics-based assays for determining whether the DANPCs are dopaminergic neuronal progenitor cells, for determining whether the DANPCs are likely to engraft when implanted into a subject brain, and for determining whether neuronal cells that are derived from the DANPCs are likely to produce dopamine after implantation.

IMPROVED BLOOD DIAGNOSTIC

Resumen de: US20260287598A1

0000 A method to quantify the abundance of Neurofilament light chain (NFL) in a blood sample, comprising the steps of adding a composition comprising a polyanionic molecule and of reacting it with at least one antibody coupled to a detection system, specifically binding to one epitope of the NFL, its use for a diagnostic application and the corresponding diagnostic kit.

GLYCINE RECEPTORS IN WHITE BLOOD CELLS AS BIOMARKERS FOR PAIN

Resumen de: US20260287599A1

Embodiments of the present disclosure pertain to methods of assessing pain in a subject by receiving one or more measured levels of glycine receptors of the subject; and correlating differentially expressed levels of the glycine receptors to pain. The methods of the present disclosure may also include a step of implementing a treatment decision based on the assessment. In some embodiments, the methods of the present disclosure may be repeated after implementing the treatment decision. Additional embodiments of the present disclosure pertain to systems for assessing pain in a subject. In some embodiments, the systems include computer-readable storage mediums with program codes that implement the methods of the present disclosure.

A METHOD FOR OPTICAL, LABEL-FREE DETECTION OF MOLECULES AT ULTRA-LOW CONCENTRATION, PARTICULARLY AS LOW AS ZEPTOMOLAR CONCENTRATION

Resumen de: US20260287585A1

Detecting a binding event of specific binding pair-forming substances, comprising includes: providing a layer of a first specific binding pair-forming substance (SBPS) on a substrate, providing an enclosure of the layer with a first dielectric medium (DM) rinsing the enclosure for a first time period with a second DM, restoring the first DM in the enclosure following the rinsing, feeding a solution of a second SBPS to the enclosure to cause an interaction between the first second SBPS following the restoring, incubating the enclosure for a second time period, the interaction including a binding event when the first and second SBPS provide a specific binding pair, detecting a shift in a parameter representative of a layer dielectric function following the incubating, comparing the shift with a threshold, whereby when the shift exceeds the threshold the binding event has occurred.

METHOD AND DEVICE FOR ESTIMATING AMOUNT OF TAU PROTEIN ACCUMULATION IN SUBJECT'S BRAIN

Resumen de: US20260287581A1

0000 The present disclosure relates to a method for estimating the amount of a tau protein accumulated in the brain. One of a capture antibody and a detection antibody which are used in the method is an antibody which recognizes an amino acid sequence in a middle part of a phosphorylated tau protein, and the other is an antibody which recognizes a phosphorylated epitope including a phosphorylated amino acid residue of the phosphorylated tau protein.

SAPONIN DERIVATIVES AS ADJUVANTS AND PHOTOAFFINITY PROBES

Resumen de: US20260285898A1

The present application relates to compounds based on a triterpene glycoside saponin scaffold, which bear an acyl chain comprising a photoreactive moiety and a terminal biotin, of general formula (I)The present application also relates to the use of said compounds and compositions thereof in the treatment of and immunization for diseases such as neurodegenerative and infectious diseases and cancers as well as its use as chemical probe in photoaffinity labeling (PAL) (for photocrosslinking with interacting partners) followed by affinity purification of the covalent complex and MS-based proteomics for target identification and elucidation of the protein receptor.

PROGNOSTIC AND PREDICTIVE VALUE OF ENDOTHELIAL DYSFUNCTION BIOMARKERS IN SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Resumen de: US20260287596A1

Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to septic shock in pediatric patients. Certain aspects of the invention relate to identifying one or more biomarkers associated with septic shock in pediatric patients in combination with one or more endothelial-derived biomarkers, receiving a dataset comprising biomarker concentrations, wherein the dataset is from a sample obtained from a pediatric patient having at least one indication of septic shock, then determining whether the biomarker concentrations of each of the at least one biomarkers are greater than one or more pre-determined cut-off biomarker concentration, wherein the level of said biomarker correlates with a predicted outcome.

High-sensitivity Assay for Serum Neurofilament Light Chain

Resumen de: US20260287580A1

0000 The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.

BINDING MOLECULES TARGETING METHYLPSEUDOURIDINE

Resumen de: WO2026198475A1

The present invention relates to an antigen-binding molecule specifically binding to methylpseudouridine or 1-methyluracil, a polynucleotide encoding it, a conjugate comprising it, and a method for producing such an antigen-binding molecule. The invention further relates to a method for detecting methylpseudouridine or 1-methyluracil, a method for detecting and/or quantifying a level of methylpseudouridine and/or 1-methyluracil, a kit for detecting presence and/or for quantifying a level of methylpseudouridine and/or 1-methyluracil, and a kit for enriching or purifying methylpseudouridine or polynucleotides containing methylpseudouridine.

METHODS OF DETECTING MULTIPLE DISEASE BIOMARKERS

Resumen de: WO2026193586A1

Disclosed herein are methods of detecting at least two biomarkers in a DNA sample from a subject, the method comprising simultaneously, in a single test, amplifying the regions of DNA containing each of the at least two types of biomarkers in the DNA sample to produce amplified DNA; sequencing, by a sequencer, the amplified DNA to produce a sequencing read; and wherein the sequencing read identifies a presence and/or an absence of the at least two types of biomarkers, optionally, outputting a report indicating the presence or absence of the at least two types biomarkers in the DNA sample wherein the at least two types of biomarkers are selected from: (i) single nucleotide variations (SNVs), and/or insertion or deletion (indel) mutations; (ii) chromosomal copy number variations (CNVs), and (iii) gene CNVs.

ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF

Resumen de: US20260285956A1

0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encephalopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

VERSATILE IMMUNODIAGNOSTIC SMARTPHONE-BASED TOOL FOR ASSESSMENT

Resumen de: WO2026198565A1

A method and related system for immunodiagnostic assessment of an antigen in a sample. A sample is mixed in a sample tube (i.e., cartridge) with magnetic beads and first visualization reagent which are both conjugated with antibodies for the antigen and, if the sample includes the antigen, forms magnetic immunocomplexes. The sample tube is attached to a base having a visualization chamber, the sample is flowed into the base from the sample tube, and the magnetic beads and, if formed, the magnetic immunocomplexes are advanced into the visualization window. A second visualization reagent adapted to react with the first visualization reagent to produce a visible change is introduced. An image is acquired of the visualization window with a smartphone to assess whether the visible change has occurred. The image of the visualization window acquired using the smartphone is evaluated to assess whether the antigen is present in the sample.

Chemical Carbonylation of Arginine in Peptides and Proteins

Resumen de: US20260285900A1

Disclosed herein are methods of oxidizing a guanidine group comprising contacting a compound or peptide having a guanidine group with a 9,10-phenanthrenequinone or derivative providing compound with an aldehyde group in place of the guanidine group. In certain embodiments, the guanidine group is an arginine amino acid within a protein. In certain embodiments, this disclosure relates to compositions comprising 9,10-phenanthrenequinone derivatives as provided herein.

Spatial Proteomics Analysis Using Wavelength-Specific Click Chemistry for Subcellular Resolution Localization

Resumen de: US20260287593A1

The present invention provides methods and systems for antibody-independent spatial proteomics analysis using wavelength-specific click chemistry. Photoactivatable click chemistry reagents responsive to distinct wavelengths (UV, blue, green, red) are introduced into biological samples and selectively activated using laser matrix systems with submicron spatial control. Wavelength-specific activation enables simultaneous labeling of proteins at multiple subcellular locations or tissue regions, followed by mass spectrometry analysis to determine spatial protein distributions with subcellular resolution. The technology eliminates antibody dependencies while providing comprehensive proteome coverage (1000+ proteins per spatial region) at significantly reduced cost and time compared to conventional methods. Applications include clinical cancer diagnostics, drug discovery screening, and research applications across diverse biological systems including cell cultures, tissue sections, and FFPE clinical specimens.

A METHOD FOR REFINED STAGE CLASSIFICATION AND DIAGNOSIS OF A HEREDITARY NEURODEGENERATIVE DISEASE

Resumen de: WO2026196014A1

The invention relates to a method for refined stage classification of a hereditary, preferably monogenic, neurodegenerative diseases mediated by an impairment of a disease-mediating gene, in disease-affected subjects. The invention also relates to diagnosis of a patient with the neurodegenerative diseases comprising classifying said patient in a stage of said disease. The subgroups react differently to treatment. In summary, the present inventors used a preclinical induced neuronal model to predict drug effectiveness in clinical trials, and have found a new dimension on prescreening patients before entering in clinical trials, thereby reducing the trial's failure.

ANTIGEN COMBINATION AND METHODS AND USES THEREOF

Resumen de: AU2025226208A1

The present invention relates to an antigen combination comprising Treponema pallidum (Tp) antigens. The present invention also relates to vectors, polynucleotides, host cells and methods for producing such antigen combinations. The present invention also relates to method and uses of such antigen combinations. The present invention also relates to compositions, assays and kits and the methods and uses thereof.

基于SERPING1的PASC相关心血管系统症状风险评估应用

Resumen de: CN122772974A

本发明涉及生物医药技术领域，尤其是涉及基于SERPING1的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPING1为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。

一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用

Resumen de: CN122775828A

0001 本发明公开一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用。本发明的方法通过主客观权重协同优化与数据标准化处理构建科学评价模型，采用合适的综合评分法实现了对加工黄精的综合质量评价，进而指导工艺参数优化，同时提升主要活性成分保留率与稳定性，实现质量与效率的双重提升。本发明还进行了加工黄精的提取物在改善衰老动物记忆下降中的功效研究，通过构建的具有阿尔茨海默病特征的动物模型的功效相关研究结果表明，包含黄精粗多糖或黄精粗皂苷的黄精加工产品能够有效改善运动障碍、认知功能障碍和脑区Aβ病理性斑块的蓄积，同时具有显著的脑部细胞凋亡抑制作用。

短链脂肪酸化合物及其用途

Resumen de: WO2025144847A1

The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.

抗UNC5C抗体及其用途

Resumen de: AU2024398768A1

Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.

增加NATO3表达和/或活性的试剂在治疗神经系统障碍中的应用

Resumen de: WO2025176707A1

The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.

抗eMTBR-tau243蛋白片段的单克隆抗体及其应用和产品

Resumen de: CN122772104A

本发明提供了一种抗eMTBR‑tau243蛋白片段的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的抗eMTBR‑tau243蛋白片段的单克隆抗体，能够特异性结合tau蛋白片段（aa225‑242），以及包含这个片段的tau蛋白片段（aa1‑256）以及全长tau蛋白（2N4R，aa1‑441），能够用于上述蛋白检测产品的制备。

一种调节Sortilin-1(SORT1)减轻阿尔茨海默病神经炎症的组合物及其应用

Nº publicación: CN122768451A 18/09/2026

Solicitante:

吉林省大术生物科技有限公司

Resumen de: CN122768451A

0001 本发明属于神经退行性疾病治疗技术领域，具体涉及通过调控神经元Sortilin‑1（SORT1）蛋白的表达或功能活性，预防、治疗阿尔茨海默病（Alzheimer's Disease,·AD）的方法与药物组合物；同时涉及调控神经元‑小胶质细胞信号通路，维持神经元内体稳态、抑制小胶质细胞异常促炎活化、减轻神经炎症、保护神经元功能的技术方案。